Less Intense Dosing Schedule for a Bone-Modifying Agent
JAMA Oncol
.
2017 Jul 1;3(7):893-894.
doi: 10.1001/jamaoncol.2016.6240.
Author
Monica N Fornier
1
Affiliation
1
Breast Medicine Service, Memorial Sloan Kettering Cancer Center, and Department of Medicine, Weill Cornell Medical College, New York, New York.
PMID:
28125761
DOI:
10.1001/jamaoncol.2016.6240
No abstract available
Publication types
Comment
MeSH terms
Breast Neoplasms*
Drug Administration Schedule
Female
Humans
Zoledronic Acid*
Substances
Zoledronic Acid